EGFR and non-small cell lung carcinoma: Targeted therapy in non-small cell lung cancer (NSCLC) had become a research hotspot.Both of gefitinib and erlotinib had already been recommended as first line treatment in epidermal growth factor receptor (EGFR) mutant advanced NSCLC patients.The study aimed to compare the effectiveness and prognosis of advanced NSCLC with gefitinib or erlotinib, as well as the cost-effectiveness ratio of the two drugs.